Israeli equity crowdfunding company OurCrowd has set up an innovation incubator in partnership with Motorola Solutions, India's Reliance Industries and Hebrew University of Jerusalem technology transfer company Yissum.

Mapping out Cancer cells and how to fight them.
Interview with Ayelet Dilion-Mashiah, NewStem CEO.

Betalin Therapeutics, Nutrino Health, and E-Shunt win top awards in first ever biomed startup competition held at MIXiii Biomed exhibition this week.

Dr. Yaron Daniely, chief executive of Yissum, Hebrew University’s technology transfer arm, and himself the driving force behind many Israeli developments in medical technology, credits the amazing performance of Israeli R&D to “chutzpah,” shown in the willingness of the country’s scientists and entrepreneurs to take on risk.

Universities in the country produce plenty of research, much of which can be turned into viable and marketable products. In that, Israel has plenty of experience: Two out of the three oldest university-based technology transfer companies in the world are here. One is Yissum, which is owned by the Hebrew University of Jerusalem and is the third tech transfer company ever set up, in 1964. The first one was in Wisconsin in the U.S., and the second was Yeda, at the Weizmann Institute, also in Israel.

The amount of sheer innovation coming out of Israel is truly impressive. "We need to exist. This is a survival mechanism, the fact that we are so flexible, so quick with ideas, so innovative. That's what keeps us alive here, not only financially but literally," Yissum's vice president of marketing, Dana Gavish-Fridman, told BioWorld Today. "There is a real understanding from a young age that our kids need to be quick, they need to innovate. 

During the recent Rethinking Food: The Future of Food Innovation event in Tel Aviv, Israel, organised by the Israel Export Institute, Dr Kevin Robinson met with Ram Reifen, a paediatric specialist in gastroenterology and nutrition and a Professor of Human Nutrition at the Hebrew University of Jerusalem’s School of Nutritional Sciences, to discuss the next big development in plant-based protein.
Supported by an initial investment of $500,000 in September 2016, from Agrinnovation, an investment fund comprising private investors and Yissum, the technology transfer arm of the Hebrew University of Jerusalem, ChiCK.P was established at the Hebrew University of Jerusalem.

Cancer patients are subject to rounds of chemotherapy treatments in which cells – both healthy and cancerous are expected to be destroyed in the process. 
Now Hebrew University researchers say they have developed a way to predict resistance to chemotherapy treatments, which can help doctors and patients better target their treatments and helping reduce the rate of resistance levels “dramatically,” from the current 50 percent.So it’s especially awful when the targeted tumors have cell mutations that are resistant to chemo or develop resistance afterwards, rendering the potentially harmful therapy ineffective and pointless.

NewStem, a startup based in Jerusalem, is developing a novel diagnostic kit for predicting resistance to chemotherapy treatments. The technology is based on the pioneering research of Prof. Nissim Benvenisty of the Azrieli Center for Stem Cells and Genetic Research  at the Hebrew University of Jerusalem.
NewStem is the only company worldwide to develop novel products based on this paradigm-changing proprietary technology, which was acquired under an exclusive license from Yissum Research Development Company, the technology-transfer company of the Hebrew University of Jerusalem.

Yissum, société de valorisation commerciale de l'université hébraïque de Jérusalem, a généré depuis 1964 près de 2 milliards de dollars de chiffre d'affaires. Si elle a misé très tôt sur les sciences de la vie, la structure a élargi son périmètre. Reportage, en amont de la Learning Expedition d'EducPros en Israël, en mai 2017.

Soy, rice and peas still dominate the plant-based protein market, but chickpeas could soon give them all a serious run for their money, predicts Israeli start-up CHiCK.P, which is seeking a strategic partner to commercialize its patent-pending process for producing highly functional ‘flavorless’ chickpea proteins.
The brainchild of Ram Reifen MD, MSc Nutrition, MBA – professor of human nutrition at the Hebrew University of Jerusalem and director of its center for nutrigenomics and functional foods - CHiCK.P has secured initial funding from Agrinnovation, an agricultural venture capital fund that’s part of the university’s Yissum technology transfer arm.
Speaking to FoodNavigator-USA during a press trip to Israel organized by the Israel Export Institute, Professor Reifen said CHiCK.P had developed concentrates with 60-90% protein and isolates with 90%+ protein, and was now looking for a partner to whom it could license the technology to produce the proteins on a commercial scale (currently production is at pilot scale).

Therapix Biosciences Ltd. (NASDAQ, TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has signed a sublicense agreement for Yissum Research Development Company of the Hebrew University Ltd.'s nasal drug delivery technology.

Under the terms of the agreement, Yissum will grant Therapix an exclusive, worldwide, sub-licensable, royalty-bearing license to its technology for the nasal delivery of cannabinoids.

The technology, developed by Professor Elka Touitou from the Institute of Drug Research at the Hebrew University of Jerusalem, facilitates administration and effective nasal absorption of tetrahydrocannabinol, or THC, the active pharmaceutical ingredient in the drugs developed by Therapix.

You’re a first-time visitor to Jerusalem, what sites are likely to arouse the strongest feelings? Naturally one would be the Western Wall, but how about the Daniel Auster Garden next to city hall?
Prof. Noam Shoval, Yonatan Schvimer and Prof. Maya Tamir – all of the Hebrew University – set out to find out what were the peak tourism experiences in Jerusalem using a combination of objective and subjective measures.

Intel agreed on Monday to pay $15.3 billion for Mobileye, an Israeli technology company that specializes in making sensors and cameras for autonomous cars, as the global microchip giant tries to expand its reach in the fast-growing sector.

The deal follows a growing partnership between Intel and Mobileye. In January, the companies announced plans to have up to 40 autonomous cars on American and European roads by the end of this year as part of trials with BMW, the German automaker.

An Israeli initiative that empowers parents to take the reins in educating their preschoolers is now about to expand to China and South Korea.
Aiming to equip parents to become their child’s first teacher, the Home Instruction for Parents and Preschool Youngsters (HIPPY) program – owned by the Yissum Research Development Company of the Hebrew University of Jerusalem will soon be coming to two Asian markets. 

From research to agricultural and technical innovation and liberal government policies, Israel is a central hub for advancing medical cannabis.

 MercuRemoval, developer of gas treatment solutions, recently announced successful results of a trial in which its technology demonstrated dramatically high efficiency in removing mercury from flue gas emission, with mercury absorption and removal rate reaching 98%. The trials are conducted in collaboration with Israel Electric Corporation (IEC). The technology was developed by Professor Yoel Sasson and Dr. Zach Barnea, both from the Casali Institute of Applied Chemistry of the Hebrew University of Jerusalem and was licensed under an exclusive worldwide agreement from Yissum, the technology transfer company of the Hebrew University.

See more information an job requirements in the attached add.

The sleepy capital is becoming a hi-tech hub to be reckoned with.

TyrNovo is developing NT219, a small molecule originally developed by Dr. Hadas Reuveni and Prof. Alexander Levitzki at the Hebrew University, and exclusively licensed from Yissum, the Hebrew University Research Development Company. TyrNovo demonstrated the potential of NT219 to overcome resistance to multiple anti-cancer drugs, by using the Patient-Derived Xenograft (PDX) models, in collaboration with Prof. Izhak Haviv from the Bar-Ilan University and Prof. M. Stemmer from Clalit HMO.

No less than 50 Israeli start ups currently develop Cannabis-related technologies, and the Hebrew University's new startup CannabiTech is here to make a change.